Advertisement

Neurological Symptoms

  • David OliverEmail author
  • Simone Veronese
Reference work entry

Abstract

Neurological disease is a major cause of disability and death across the world. There is increasing evidence that palliative care is effective in managing symptoms, maintaining and improving quality of life and helping patients and families cope with the deterioration. As the disease progression varies, both between diseases and for individuals. palliative care may be involved for varying periods of time, and may need to be involved episodically throughout the disease progression. Careful assessment of all the issues – physical, psychosocial and spiritual – will allow appropriate management and support for patients and families. Carer support is very important as families face all the issues of coping with a progressive disease. Recognition of the later stages of life is helpful in enabling patients, families and professionals to be able to prepare for the dying phase and manage all the issues appropriately.

References

  1. Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, et al. Efficacy of oral risperidone, haloperidol or placebo for symptoms of delirium among patient in palliative care. A randomised controlled trial. JAMA Int Med. 2017;177:34–42.CrossRefGoogle Scholar
  2. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–73.  https://doi.org/10.1002/mds.25475.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Allen RP, Picchietti D, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Alves G, Forsaa EB, et al. Epidemiology of Parkinson’s disease. J Neurol. 2008;5:18–32.CrossRefGoogle Scholar
  5. Anderson JF, Augoustakis LV, et al. End-of-life decision-making in individuals with locked-in syndrome in the acute period after brainstem stroke. Intern Med J. 2010;40:61–5.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Arenella C. Coma and persistent vegetative state: an exploration of terms. 2017. https://americanhospice.org/caregiving/coma-and-persistent-vegetative-state-an-exploration-of-terms/. Retrieved 20 Apr 2017.
  7. Bade P. Improving communication when hearing loss is present #241. J Palliat Med. 2011;14(7):876–7.  https://doi.org/10.1089/jpm.2011.9672. PMID: 21699426.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bagai A, Thavendiranathan P, et al. Does this patient have hearing impairment? JAMA. 2006;295:416–28.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Balta O, Acar U, et al. Review of 306 evisceration surgeries performed between 2005 and 2013. Turk J Med Sci. 2016;46:463–7.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Bauer G, Gerstenbrand F, et al. Varieties of the locked-in syndrome. J Neurol. 1979;221:77–91.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147–57.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Bisdorff A, Bosser AG, et al. The epidemiology of vertigo, dizziness, and unsteadiness and its links to co-morbidities. Front Neurol. 2013;4(29).  https://doi.org/10.3389/fneur.2013.00029. eCollection 2013.
  13. Bouhassira D, Attal N, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bryan Young, G. Stupor and coma in adults 2015; UpToDate.Google Scholar
  15. Buhmann C, Wrobel N, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol. 2017;264:758–69.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Calsina-Berna A, Garcia-Gomez G, Gonzales-Baboteo J, Porta-Sales J. Threatment of chronic hiccups in cancer patients: a systematic review. J Pall Med. 2012;15:1142–50.CrossRefGoogle Scholar
  17. Carlos K, Prado GF, et al. Benzodiazepines for restless legs syndrome. Cochrane Database Syst Rev. 2017; 20(3). CD006939.  https://doi.org/10.1002/14651858. CD006939.pub2. Review.PMID: 28319266.
  18. Costigan M, Scholz J, et al. Neuropathic pain: a maladaptive response of the nervous system to damage. Ann Rev Neurosci. 2009;32:1–32.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Cruccu G, Truini A. Tools for assessing neuropathic pain. PLoS Med. 2009;6:e1000045.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Cuenca J, Glazebrook C, Kendall T, Hedderly T, Heyman I, et al. BMC Psychiatry. 2015;15:46. Published online 11 Mar 2015.  https://doi.org/10.1186/s12888-015-0430-0.
  21. Dal Bello-Haas V, Florence JM, Krivickas LS. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;2:CD005229.Google Scholar
  22. de Oliveira CO, Carvalho LB, et al. Opioids for restless legs syndrome. Cochrane Database Syst Rev. 2016; 29(6). CD006941.  https://doi.org/10.1002/14651858. CD006941.pub2. Review.PMID:27355187.
  23. Doty RL. Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis. 2012;46:527–52.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Doty RL, Deems DA, et al. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44.PubMedCrossRefPubMedCentralGoogle Scholar
  25. Ducreux D, Attal N, et al. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia. Brain. 2006;129:963–76.PubMedCrossRefPubMedCentralGoogle Scholar
  26. Dworkin RH, Backonja M, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524–34.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Dworkin RH, O’Connor AB, et al. Pharmacologic management of neuropathic pain: evidence based recommendations. Pain. 2007;132:237–51.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Dworkin RH, O’Connor AB, et al. Recommendations for the pharmacological Management of Neuropathic Pain: an overview and literature update. Mayo Clinic Proc. 2010;85(3 Suppl):S3–S14.CrossRefGoogle Scholar
  29. Feinberg L. Moving toward person-and family-centered care. Public Policy Aging Rep. 2014;24:97–101.CrossRefGoogle Scholar
  30. Fereshtehnejad SM, Shafieesabet M, et al. Restless legs syndrome in patients with Parkinson’s disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurol Scand. 2015;131:211–8.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Finucane AM, Lugton J, Kennedy C, Spiller JA. The experiences of caregivers of patients with delirium, and their role in its management in palliative care settings: an integrative literature review. Psychooncolgy. 2017;26:291–300.CrossRefGoogle Scholar
  32. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy. Definition proposed by the international league against epilepsy and the International Bureau for Epilepsy. Epilepsia. 2005;46:470–2.PubMedCrossRefPubMedCentralGoogle Scholar
  33. Galindo-Ferreiro A, Akaishi P, et al. Retrobulbar injections for blind painful eyes: a comparative study of Retrobulbar alcohol versus chlorpromazine. J Glaucoma. 2016;25:886–90.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Haehner A, Boesveldt S, et al. Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord. 2009;15:490–4.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Haehner A, Habersack A, et al. Early Parkinson’s disease patients on rasagiline present with better odor discrimination. J Neural Transm. 2015;122:1541–6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Haig AJ, Katz RT, et al. Mortality and complications of the locked-in syndrome. Arch Phys Med Rehabil. 1987;68:24–7.PubMedPubMedCentralGoogle Scholar
  37. Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs. 2003;17:85–100.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Hawkes C. Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol. 2006;63:133–51.PubMedPubMedCentralGoogle Scholar
  39. Heckmann JG, Dinkel HP. Recovery of locked-in syndrome in central pontine myelinolysis. Am J Case Rep. 2013;14:219–20.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Hogl B, Comella C. Therapeutic advances in restless legs syndrome (RLS). Mov Disord. 2015;30:1574–9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Hoogwout SJ, Paananen MV, et al. Musculoskeletal pain is associated with restless legs syndrome in young adults. BMC Musculoskelet Disord. 2015;16:015–0765.CrossRefGoogle Scholar
  42. Hosie A, Davidson PM, Agar M, Sanderson CR, Phillips J. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Pall Med. 2013;27:486–98.CrossRefGoogle Scholar
  43. Hosomi K, Morris S, Sakamoto T, Taguchi J, Maruo T, et al. Daily repetitive transcranial magnetic stimulation for post stroke upper limb paresis in the subacute period. J Stroke Cerebrovasc Dis. 2016;25:1655–64.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Hummel T, Landis BN, et al. Smell and taste disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2011;10:Doc04.PubMedPubMedCentralGoogle Scholar
  45. Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev. 2016;10:CD009419.PubMedPubMedCentralGoogle Scholar
  46. Kaub-Wittemer D, Steinbuchel N, et al. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Symptom Manag. 2003;26:890–6.CrossRefGoogle Scholar
  47. Kerber KA, Baloh RW. The evaluation of a patient with dizziness. Neurol Clin Pract. 2011;1:24–33.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Kestelyn PG, Cunningham ET. HIV/AIDS and blindness. Bull World Health Organ. 2001;79:208–13.PubMedPubMedCentralGoogle Scholar
  49. Klockgether T. Ataxias. Parkinsonisms Relat Disord. 2007;13:S391–4.CrossRefGoogle Scholar
  50. Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol. 2010;9:94–104.PubMedCrossRefPubMedCentralGoogle Scholar
  51. Kok VC, Lee P-H. Management of Hypoglycemia in nondiabetic palliative care patients: a prognosis-based approach. Palliat Care. 2016;10:1–5.PubMedPubMedCentralGoogle Scholar
  52. Kompanje EJ. End-of-life decision-making in patients with locked-in syndrome. Intern Med J. 2010;40:607–8.  https://doi.org/10.1111/j.1445-5994.2010.02227.x.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Kuehlmeyer K, Racine E, et al. Diagnostic and ethical challenges in disorders of consciousness and locked-in syndrome: a survey of German neurologists. J Neurol. 2012;259:2076–89.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Kumar A, Weber MH, Gokaslan Z, et al. Metastatic spinal cord compression and steroid treatment: A systematic review. Clin Spine Surg. 2017;30:156–163.PubMedCrossRefPubMedCentralGoogle Scholar
  55. Lahrmann H, Grisold W. Locked-in syndrome. In: Voltz R, Bernat JL, Borasio GD, et al., editors. Palliative care in neurology. Oxford: Oxford University Press; 2004. p. 135–42.Google Scholar
  56. Laureys S, Pellas F, et al. The locked-in syndrome: what is it like to be conscious but paralyzed and voiceless? Prog Brain Res. 2005;150:495–611.PubMedCrossRefPubMedCentralGoogle Scholar
  57. Levack P, Graham J, Collie D, et al. Scottish Cord Compression Study Group. Don’t wait for a sensory level–listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. Clin Oncol (R Coll Radiol). 2002;14:472–80.Google Scholar
  58. Mackie S, Winkelman JW. Long-term treatment of restless legs syndrome (RLS): an approach to Management of Worsening Symptoms, loss of efficacy, and augmentation. CNS Drugs. 2015;29:351–7.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Maddalena V, O’Shea F, et al. Palliative and end-of-life care in Newfoundland’s deaf community. J Palliat Care. 2012;28:105–12.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Malik FA, Hall EJ, Edmonds P. The palliative management of raised intra-cranial pressure. In: Booth S, Bruera E, editors. Primary and metastatic brain tumours. Oxford: Oxford University Press; 2004. p. 61–81.CrossRefGoogle Scholar
  61. Maschio M. Brain tumour-related epilepsy. Curr Neuropharmacol. 2012;10:124–33.PubMedPubMedCentralCrossRefGoogle Scholar
  62. McCusker EA, Rudick RA, et al. Recovery from the ‘locked-in’ syndrome. Arch Neurol. 1982;39:145–7.PubMedCrossRefPubMedCentralGoogle Scholar
  63. McShane R, Nagy Z, et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer’s pathology. J Neurol Neurosurg Psychiatry. 2001;70:739–43.PubMedPubMedCentralCrossRefGoogle Scholar
  64. MD Guidelines. 2017. Available from: http://www.mdguidelines.com/dizziness-and-giddiness.
  65. Mercadante S, Porzio G, Valle A, Fusco F, Aielli F, Adile C, Casuccio A. Orphan symptoms in advance cancer patients followed at home. Support Care Cancer. 2013;21:3525–8.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Mercadante S, Adile C, Ferrera P, Corttegiani A, Casuccio A. Delirium assessed by memorial assessment scale in advance cancer patients admitted to an acute palliative/supportive care unit. Curr Med Res Opin. 2017;33:1–16.  https://doi.org/10.1080/03007995.2017.1315332.CrossRefGoogle Scholar
  67. National Institute for Health and Care Excellence (NICE). Metastatic spinal cord compression in adults: risk assessment, diagnosis and management. 2008. www.nice.org.uk/guidance/cg75.
  68. National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. NICE Guideline NG 42. NICE 2016. www.nice.org.uk/guidance/NG42
  69. Neuhauser H, et al. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo controlled trial. Neurology. 2003;60:882–3.PubMedCrossRefPubMedCentralGoogle Scholar
  70. Nichols DA, Allen RP, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Inter Med. 2003;163:2323–9.CrossRefGoogle Scholar
  71. Nordin S, Paulsen JS, et al. Sensory- and memory-mediated olfactory dysfunction in Huntington’s disease. J Int Neuropsychol Soc. 1995;1:281–90.PubMedCrossRefPubMedCentralGoogle Scholar
  72. Ohayon MM, O’Hara R, et al. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–95.PubMedCrossRefPubMedCentralGoogle Scholar
  73. Oliver D. The prevention and treatment of seizures in intra-cranial malignancy. In: Booth S, Bruera E, editors. Palliative care consultations: primary and metastatic brain tumours. Oxford: Oxford University Press; 2004. p. 49–59.CrossRefGoogle Scholar
  74. Pall HS. Involuntary movements. In: Williams AC, editor. Patient care in neurology. Oxford: Oxford University Press; 1999. p. 127–43.Google Scholar
  75. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. 2011;24:346–53.  https://doi.org/10.1097/WCO.0b013e328347b307.CrossRefPubMedPubMedCentralGoogle Scholar
  76. Pi J, Kang Y, Smith M, Earl M, Norigian Z, McBride A. A review in the treatment of oncologic emergencies. J Oncol Pharm Practice. 2016;22:625–38.CrossRefGoogle Scholar
  77. Ramjit AL, Sedig L, et al. The relationship between anosmia, constipation, and orthostasis and Parkinson’s disease duration: results of a pilot study. Int J Neurosci. 2010;120:67–70.PubMedCrossRefPubMedCentralGoogle Scholar
  78. Regard C, Reynolds J, Watson B, Matthews D, Gibson L, Clarke C. Understanding distress in people with severe communication difficulties: developing and assessing the disability distress assessment tool (DisDAT). J Intellect Disabil Res. 2007;51:277–92.CrossRefGoogle Scholar
  79. Rousseau MC, Pietra S, et al. Evaluation of quality of life in complete locked-in syndrome patients. J Palliat Med. 2013;16:1455–8.PubMedCrossRefPubMedCentralGoogle Scholar
  80. Rousseau MC, Baumstarck K, et al. Quality of life in patients with locked-in syndrome: Evolution over a 6-year period. Orphanet J Rare Dis. 2015;10:88.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372–3.  https://doi.org/10.1136/jnnp.2008.144964. Epub 2010 Jun 11. Review.CrossRefGoogle Scholar
  82. Saita L, Polastri D, et al. Visual disturbances in advanced cancer patients: clinical observations. J Pain Symptom Manag. 1999;17:224–6.CrossRefGoogle Scholar
  83. Savage P, Sharkey R, Kua T, Schofield L, Ricahrdson D, et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. Q J Med. 2014;107:277–82.CrossRefGoogle Scholar
  84. Schnakers C, Perrin F, et al. Detecting consciousness in a total locked-in syndrome: an active event-related paradigm. Neurocase. 2009;15:271–7.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Scholz J, Mannion RJ, et al. A novel tool for the assessment of pain: validation in low back pain. PLoS Med. 2009;6:7.CrossRefGoogle Scholar
  86. Shprecher S, Kurlan R. The management of tics. Mov Disord. 2009;24:15–24.  https://doi.org/10.1002/mds.22378.CrossRefPubMedPubMedCentralGoogle Scholar
  87. Silver B, Grover KM, et al. Recovery in a patient with locked-in syndrome. Can J Neurol Sci. 2006;33:246–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. Smith HS, Busracamwongs A. Management of hiccups in the palliative care population. Am J Hosp Palliat Care. 2003;20:149–54.PubMedCrossRefPubMedCentralGoogle Scholar
  89. Smith AK, Jain N, et al. Hearing loss in palliative care. J Palliat Med. 2015;18:559–62.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Swartz R, Longwell P. Treatment of vertigo. Am Fam Physician. 2005;71:1115–22.PubMedPubMedCentralGoogle Scholar
  91. Thadani VM, Rimm DL, et al. Locked-in syndrome for 27 years following a viral illness: clinical and neurologic findings. Neurology. 1991;41:498–500.PubMedCrossRefPubMedCentralGoogle Scholar
  92. The Palliative Care Formulary. 2016. Available from: http://www.palliativedrugs.com/.
  93. Tradounsky G. Seizures in palliative care. Can Fam Physician. 2013;59:951–5.PubMedPubMedCentralGoogle Scholar
  94. Uecker FC, Olze H, et al. Longitudinal testing of olfactory and gustatory function in patients with multiple sclerosis. PLoS One. 2017;2(1):e0170492.  https://doi.org/10.1371/journal.pone.0170492. eCollection 2017.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Walters AS, Winkelmann J, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001;16:1105–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the pain assessment in advanced dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4:9–15.PubMedCrossRefPubMedCentralGoogle Scholar
  97. Weinstein BE. Palliative care: defining the role of the audiologist. Hear J. 2015;68:23–4.CrossRefGoogle Scholar
  98. Wenning GK, Shephard B, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand. 1995;91:247–50.PubMedCrossRefPubMedCentralGoogle Scholar
  99. Wijdicks EF, Bamlet WR, et al. Validation of a new coma scale: The FOUR score. Ann Neurol. 2005;58:585–93.PubMedCrossRefPubMedCentralGoogle Scholar
  100. Woelk CJ. Managing hiccups. Can Fam Physcian. 2011;57:672–5.Google Scholar
  101. World Health Organization. Palliative care. 2002. www.who.int/cancer/palliative/definition/en/. Accessed 26 July 2015.
  102. Yeh P, Walters AS, et al. Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. 2012;16:987–1007.PubMedCrossRefPubMedCentralGoogle Scholar
  103. Yorston D. The role of the ophthalmologist in advanced disease. In: Dunn G, Johnson A, editors. Surgical palliative care; 2004. Oxford Scholarship Online.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Tizard CentreUniversity of KentCanterburyUK
  2. 2.Fondazione FAROpalliative careTorinoItaly

Personalised recommendations